AIM ImmunoTech (AIM) Touts Ampligen's Ebola Prophylactic Potential as Outbreaks Spread; Shares Fall

AIM ImmunoTech Inc. (AIM) on May 28, 2026 said its drug Ampligen demonstrated prophylactic potential against the Ebola virus, seeking to capitalize on renewed outbreaks in West Africa. The announcement failed to lift its stock, which declined 3.1% to $2.20 in afternoon trading. The company highlighted recent preclinical studies showing that Ampligen, an immune system modulator, triggered protective immune responses in animal models exposed to Ebola. AIM aims to position the drug as a preventive option for at-risk populations, though it has yet to begin clinical trials for this indication. The push comes as the World Health Organization confirmed new Ebola cases in Guinea. Investors appeared unswayed by the pipeline update. Analysts cited AIM’s limited cash reserves and a history of development delays. Ampligen is already under investigation for chronic fatigue syndrome and certain cancers, but regulatory approval remains elusive. The Ebola effort adds to a broad portfolio that has yet to generate product revenue.